August 9, 2007
Quarterly loss triples at Caliper
By Matthew L. Brown
Caliper Life Sciences Inc., a Hopkinton-based drug research services company, reported a second quarter net loss of $6.3 million compared to a loss of $2.1 million for the same period a year ago.
The company said the losses were incurred as Caliper made $35.3 million in revenue, a 45 percent increase over the second quarter of 2006.
Caliper said its revenue growth was the result of its Aug. 2006 acquisition of Xenogen, a Hopkinton-based biotechnology company, and Caliper's newfound ability to sell Xenogen's products.
However, Caliper reported that the gains it made from the Xenogen acquisition were offset by a drop in license fees and contract revenue, which dropped by 20 percent compared to the second quarter of 2006. The company said a significant part of the drop in licensing fees was that it no longer has a licensing agreement with Canon U.S. Life Sciences Inc.
The company said it expects revenue growth between 19 percent and 34 percent for the third quarter.
The company said the losses were incurred as Caliper made $35.3 million in revenue, a 45 percent increase over the second quarter of 2006.
Caliper said its revenue growth was the result of its Aug. 2006 acquisition of Xenogen, a Hopkinton-based biotechnology company, and Caliper's newfound ability to sell Xenogen's products.
However, Caliper reported that the gains it made from the Xenogen acquisition were offset by a drop in license fees and contract revenue, which dropped by 20 percent compared to the second quarter of 2006. The company said a significant part of the drop in licensing fees was that it no longer has a licensing agreement with Canon U.S. Life Sciences Inc.
The company said it expects revenue growth between 19 percent and 34 percent for the third quarter.
WBJ Web Partners
Most Recent
Most Recent
0 Comments